Amplia Therapeutics
-
Ticker
ATX
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 1-10 Employees
- Based in Melbourne, Australia
Amplia Therapeutics Limited is a pharmaceutical company advancing a pipeline of FAK inhibitors for cancer and fibrosis. The lead molecule, AMP945, is a “pure play” inhibitor with superior specificity.
REPORT RATINGS
4.8 / 5.0 (53)
Amplia Therapeutics reports have an aggregate usefulness score of 4.8 based on 53 reviews.
Amplia Therapeutics
Most Recent Annual Report
MOST RECENT
2023 Annual Report
Older/Archived Annual Reports